Photopharmacology for vision restoration

Curr Opin Pharmacol. 2022 Aug:65:102259. doi: 10.1016/j.coph.2022.102259. Epub 2022 Jun 21.

Abstract

Blinding diseases that are caused by degeneration of rod and cone photoreceptor cells often spare the rest of the retinal circuit, from bipolar cells, which are directly innervated by photoreceptor cells, to the output ganglion cells that project axons to the brain. A strategy for restoring vision is to introduce light sensitivity to the surviving cells of the retina. One approach is optogenetics, in which surviving cells are virally transfected with a gene encoding a signaling protein that becomes sensitive to light by binding to the biologically available chromophore retinal, the same chromophore that is used by the opsin photo-detectors of rods and cones. A second approach uses photopharmacology, in which a synthetic photoswitch associates with a native or engineered ion channel or receptor. We review these approaches and look ahead to the next generation of advances that could reconstitute core aspects of natural vision.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Humans
  • Optogenetics
  • Retina*
  • Retinal Cone Photoreceptor Cells* / metabolism
  • Rod Opsins / genetics
  • Rod Opsins / metabolism

Substances

  • Rod Opsins